# BDC-4182

Source: https://onco.cc/drugs/bdc-4182/  
OnCo record `bdc-4182` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BDC-4182 is an experimental monoclonal antibody from Bolt Biotherapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.

## Summary

BDC-4182 is a monoclonal antibody developed by Bolt Biotherapeutics. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: A 'Boltbody' immune-stimulating antibody conjugate (ISAC) combining an anti-Claudin 18.2 monoclonal antibody with a TLR7/8 dual agonist, working through immune activation (inducing immunological memory) rather than direct cytotoxicity. ClinicalTrials.gov describes the intervention as: Immune stimulating antibody conjugate (ISAC), consisting of an anti-claudin 18.2 monoclonal antibody conjugated to a TLR 7/8 dual agonist. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer. The largest, NCT06921837, plans to enrol 122 participants with primary completion expected 2027-05. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: A 'Boltbody' immune-stimulating antibody conjugate (ISAC) combining an anti-Claudin 18.2 monoclonal antibody with a TLR7/8 dual agonist, working through immune activation (inducing immunological memory) rather than direct cytotoxicity.

## Sources

- ClinicalTrials.gov: trials of BDC-4182: https://clinicaltrials.gov/search?intr=BDC-4182
- Sponsor pipeline page: https://boltbio.com/pipeline/

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Bolt Biotherapeutics](https://onco.cc/companies/bolt-biotherapeutics/)
- trials: [A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer](https://onco.cc/trials/nct06921837/)

---
JSON: https://onco.cc/api/v1/entities/bdc-4182.json